Neuroscientists at Brigham and Women's Hospital were searching for clues to the development of MS when they found an antibody with cancer-fighting…

La Jolla Pharmaceutical has posted a full look at data from a phase 3 trial of its vasodilatory shock candidate LJPC-501.

GI Dynamics announced Thursday that the CE mark for its EndoBarrier intestinal liner was suspended.

Argenx’s IPO fundraising total has come to a stop at $144.7 million, more than 50% above its initial target.

RM Global has created a VC fund dedicated to the FutuRx biotech incubator Johnson & Johnson set up with OrbiMed and Takeda.

AB Science says its drug candidate masitinib has slowed down progression in a late-stage trial, but its checkered development history means the reaction is…

The FDA’s Gastroenterology-Urology Devices Panel recommended TransMedics’ lung transport system for approval.

Iterum has completed a $65 million series B to equip it to take its antibiotic sulopenem through phase 3.

Verily hired former FDA chief Robert Califf, Theranos named a former Abbott Diagnostics exec as head of product development, Biogen's CSO quietly stepped…